Aclaris Therapeutics (ACRS)
4.34
-0.02 (0.46%)
Upcoming Events
Latest Headlines
Form 4 Aclaris Therapeutics, For: Jun 04 Filed by: Molineaux Christopher P.
June 8, 2026 4:15 PM - SEC Filing
Form 4 Aclaris Therapeutics, For: Jun 04 Filed by: MILANO VINCENT
June 8, 2026 4:15 PM - SEC Filing
Form 4 Aclaris Therapeutics, For: Jun 04 Filed by: Mehra Anand
June 8, 2026 4:15 PM - SEC Filing
Form 4 Aclaris Therapeutics, For: Jun 04 Filed by: Humphries William D.
June 8, 2026 4:15 PM - SEC Filing
Form 4 Aclaris Therapeutics, For: Jun 04 Filed by: SCHIFF ANDREW N
June 8, 2026 4:15 PM - SEC Filing
Form 4 Aclaris Therapeutics, For: Jun 04 Filed by: GOWEN MAXINE
June 8, 2026 4:15 PM - SEC Filing
Form 8-K Aclaris Therapeutics, For: Jun 04
June 4, 2026 4:02 PM - SEC Filing
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026 8:30 AM - Globe NewsWire
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.
May 12, 2026 9:49 PM - SEC Filing
Aclaris Therapeutis (ACRS) PT Raised to $4 at Stifel
May 8, 2026 12:28 PM - StreetInsider
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
May 8, 2026 8:30 AM - Globe NewsWire
Form 10-Q Aclaris Therapeutics, For: Mar 31
May 7, 2026 4:35 PM - SEC Filing
Form 8-K Aclaris Therapeutics, For: May 07
May 7, 2026 7:15 AM - SEC Filing
Aclaris Therapeutics (ACRS) Tops Q1 EPS by 1c
May 7, 2026 7:03 AM - StreetInsider
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
May 7, 2026 6:59 AM - Globe NewsWire
Form 4 Aclaris Therapeutics, For: May 01 Filed by: Hall Jesse Wayne
May 5, 2026 4:16 PM - SEC Filing
Aclaris Therapeutis (ACRS ) PT Raised to $11 at Piper Sandler
May 5, 2026 6:50 AM - StreetInsider
Guggenheim Starts Aclaris Therapeutis (ACRS) at Buy
May 4, 2026 4:26 PM - StreetInsider
Form 8-K Aclaris Therapeutics, For: Apr 28
April 28, 2026 6:45 AM - SEC Filing
Aclaris reports positive phase 1 trial results for ATI-052 antibody
April 28, 2026 6:30 AM - StreetInsider
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific An
April 28, 2026 6:30 AM - Globe NewsWire
Form 4 Aclaris Therapeutics, For: Apr 27 Filed by: Leonard Braden Michael
April 27, 2026 7:27 PM - SEC Filing
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.
April 27, 2026 7:26 PM - SEC Filing
Aclaris Therapeutics to release clinical trial results April 28
April 27, 2026 4:46 PM - StreetInsider
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
April 27, 2026 4:45 PM - StreetInsider
Form ARS Aclaris Therapeutics, For: Dec 31
April 23, 2026 7:48 AM - SEC Filing
Form DEFA14A Aclaris Therapeutics,
April 23, 2026 7:47 AM - SEC Filing
Form DEF 14A Aclaris Therapeutics, For: Jun 04
April 23, 2026 7:46 AM - SEC Filing
Oppenheimer Starts Aclaris Therapeutis (ACRS) at Outperform
April 16, 2026 6:40 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Aclaris Therapeutis (ACRS)
April 15, 2026 7:21 AM - StreetInsider
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
April 8, 2026 8:30 AM - StreetInsider
Form SCHEDULE 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
April 7, 2026 6:00 PM - SEC Filing
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
March 27, 2026 10:10 AM - StreetInsider
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: VANGUARD GROUP INC
March 26, 2026 3:06 PM - SEC Filing
Aclaris Therapeutics to present ATI-2138 atopic dermatitis trial data
March 20, 2026 11:00 AM - StreetInsider
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 20, 2026 11:00 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Aclaris Therapeutis (ACRS)
March 19, 2026 6:59 AM - StreetInsider
Aclaris completes enrollment in phase 2 atopic dermatitis trial
March 18, 2026 6:55 AM - StreetInsider
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
March 18, 2026 6:55 AM - StreetInsider
Full Article List
